Ascletis Pharma Advances ASC35 for Obesity Treatment
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Ascletis Pharma, Inc. ( (HK:1672) ) is now available.
Ascletis Pharma Inc. has announced the selection of ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist, for clinical development. ASC35 has shown promising results in preclinical studies, demonstrating a longer half-life and greater efficacy in weight reduction compared to tirzepatide, positioning it as a potentially best-in-class treatment for obesity. The company plans to submit an Investigational New Drug Application for ASC35 to the FDA by the second quarter of 2026, which could significantly impact its market positioning and offer scalability advantages in manufacturing.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$10.50 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
More about Ascletis Pharma, Inc.
Ascletis Pharma Inc. is a biopharmaceutical company focused on developing innovative therapies for the treatment of diseases such as obesity. The company utilizes advanced technologies like Artificial Intelligence-Assisted Structure-Based Drug Discovery and Ultra-Long-Acting Platform to create its products.
Average Trading Volume: 9,542,980
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.51B
Learn more about 1672 stock on TipRanks’ Stock Analysis page.
